News

The Meharry and Vanderbilt-based expert shares insights into reaching less trustful populations on the first podcast episode.

Fundamental aspects of immunity to SARS-CoV-2 remain elusive. Here is an examination of some potential clues to protection.

A collection of expert perspectives on what the virus itself may mean for future crises.

New ACTT-2 data shows a marked benefit from the combination regimen versus lone remdesivir.

ACTT-1 findings for the Gilead antiviral show it improved chance of clinical improvement by 50% in very ill COVID-19 patients.

In consideration of the idea that the pandemic may lead to greater knowledge and adoption of preventive health measures.

The new pathogen panel will distinguish between 20 different common and serious respiratory infections, giving clinicians more confidence in flu season diagnoses.

Numerous candidates are in late-stage assessment. An expert shares what the diverse agents should show before being considered for regulation.

A pair of investigative monoclonal antibodies from Lilly show promise for mitigating mild to moderate COVID-19 risks of escalation.

The new guidance bucks against the White House's campaign message of an available prophylaxis by the election.

Perspective on the ongoing independent safety reviews for one of the more promising vaccine candidates.

Within NIH is the National Center for Advancing Translational Sciences (NCATS) and they will oversee the grant awards. Christopher Austin, MD, director, NCATS, discusses the specifics of the 2 trials being expanded.

Prone positioning has been found to improve outcomes for mechanically ventilated patients with COVID-19, and a new study suggests the strategy may also benefit conscious patients requiring continuous positive airway pressure.

Fauci also shares suggestions for college campus to mitigate community-based spread while classes continue.

The President's hospital stay continues through a third day, with conflicting messages on his health and an escalation in therapy.

A discussion with an expert on the particularities of the vaccines, which vary in temperature climate requirements and dosages.

A collection of perspectives on how the virus is affecting patients outside of infectious disease.

Why the AstraZeneca & Oxford University trial's pause due to an adverse event was a sign to Fauci the vaccine monitoring systems are working.

New CDC data showed adults aged 20-29 made up more than 20% of all confirmed cases from June-August of this year.

As concerns are raised about prospective vaccines and their safety and efficacy, infectious disease experts offer support and insights about the development process.

Aethlon Medical is developing its proprietary Hemopurifier, which is a therapeutic device designed for the single use depletion of circulating viruses.

President Donald Trump broke the news last night via Twitter.

“Higher-quality” evaluations of these technologies are “urgently needed,” researchers say.

Brad Spellberg, MD, emphasizes his belief the Affordable Care Act needs to be retained so as long as the pandemic persists.

International collaboration, fast action, and mRNA platform technology led to phase 3 trials in record time—without compromise of safety standards.

Putting these findings in the context of the ongoing coronavirus crisis was especially important, the study authors said.

A study found that 14% of them experienced cardiac arrest within two weeks of being admitted to the ICU.

The agency requested data this week, following the pause of large-scale international assessment after a non-fatal serious adverse event was reported in a UK participant earlier this month.

Principal investigator Richard Becker, MD, director of the University of Cincinnati Heart, Lung and Vascular Institute discusses the phase 2 clinical trial for razuprotafib.

The country is split on certain strategies and a potential vaccine. Here's why the message needs to go from national to regional.